The latest headlines across every section, pulled from official and open-access sources.
The focus of the company is SERP-01, an in vivo base editing program targeting AATD developed in China and licensed from YolTech Therapeutics.
An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch of new companies to fly its drug candidates forward.
Half a year after toppling Genentech’s eye medicine giant Vabysmo in an early trial, Texas biotech Ollin Biosciences has lassoed a $330 million series B to push its winning contender through a multi-trial phase 3 gauntlet.
Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple targets.
Omnipod maker Insulet has hired Divakar Ramakrishnan, Ph.D., as its new Chief Research and Development Officer.
On Tuesday afternoon at the 2026 Biotechnology Innovation Organization conference in San Diego, Flagship Pioneering announced a research collaboration with Lean Business Services within the well-appointed Saudi Arabia pavilion in the heart of the conference’s exhibition floor.
Access Vascular, a Massachusetts-based device maker that focuses on intravenous catheters, inked a partnership deal with medical supply giant Medline to help roll out a new line of catheters.
Abbott has become the latest company to team up with Alzheimer’s disease blood test developer ALZpath.
Novartis is paying Antares Therapeutics $105 million upfront in a deal worth up to $1.9 billion to generate small molecules against historically undruggable oncology targets.
Amid a bustling fundraising week for biotechs, the U.K.’s RQ Bio is adding $115 million to its coffers to advance a long-acting antibody for flu prevention.
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo treatment to a massive survival benefit versus late-day infusion in non-small cell lung cancer.
Officials are planning to study Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir, which gained prominence during the COVID-19 pandemic, against the Bundibugyo ebolavirus.
Irish CRO giant Icon this week made Microsoft its technology partner as the organization advances its plan to increase investment in AI over the next three years. Microsoft’s Copilot and data infrastructure will be implemented enterprise-wide to further scale Icon’s agentic AI platform, Orbis.
Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in an all-stock reverse merger with RNA specialist Remix Therapeutics.
Ionis Pharmaceuticals has offloaded regional rights to its near-approval rare disease asset zilganersen, pocketing $30 million upfront from Recordati for an ex-U.S. license to the drug candidate.
The FDA has sent an End of Enforcement notice to consumer wearable device company Whoop, putting a formal end to the agency’s investigation into its blood pressure tech use.
TechBio outfit Immunai is continuing its parade of Big Pharma partnerships with its third such pact this year, this time with German drugmaker Boehringer Ingelheim.
A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before a potential U.S. launch of the therapy.
Dr. Israel Lowy remembers the days when he and his oncology immunotherapy colleagues were assigned tables in the distant east wing of the American Society of Clinical Oncology conference in Chicago. They would watch aficionados walk by, scoffing at these iconoclastic researchers pushing an alternative way to treat cancer.
In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D., Ph.D., detailed how the company leveraged two recent deals to quickly build up its portfolio in Alzheimer’s disease as part of a multi-step roadmap to establish its independent capabilities in the U.S.
Puerto Rico is building on its pharma manufacturing legacy to attract advanced therapy developers seeking scale, regulatory alignment and speed.
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered discovery platform it picked up in 2022.
EMD Serono, Merck KGaA’s North American healthcare arm, has promoted from within to replace its retiring head of global commercial strategy, Andrew Paterson. Taking the commercial wheel is Miguel Fernández Alcalde, who’s spent over a decade at the company.
Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, dubbed “007,” next year.